Form 4: Monopar Therapeutics COO Equity Vesting Transaction

Monopar Therapeutics Chief Operating Officer Andrew Cittadine acquired 3,514 shares via RSU vesting and withheld 1,571 shares for taxes.

Summary

• Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, executed a transaction involving the vesting and settlement of restricted stock units (RSUs).
• The reporting person acquired 3,514 shares of common stock upon the vesting of RSUs.
• The issuer withheld 1,571 shares to satisfy tax withholding obligations at a price of $54.79 per share.
• Following these transactions, the reporting person holds 52,669 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents standard administrative equity vesting rather than a strategic shift or market-driven trade.

Positives

• The transaction reflects the ongoing vesting of equity compensation, aligning the interests of the COO with long-term shareholder value.

Negatives

• The withholding of 1,571 shares for tax purposes represents a reduction in the potential net share ownership for the executive.

Risks

• The value of the shares is subject to market volatility, which impacts the tax withholding calculation and the ultimate value of the equity compensation.

Future Outlook

The reporting person continues to hold unvested RSUs that will vest quarterly through December 31, 2028, per the established grant schedules.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of executive compensation and does not signal a change in corporate strategy or market outlook.

Comparison to Industry Standards

• The use of RSU vesting and net-settlement (withholding shares for taxes) is a standard practice for executive compensation in the biotechnology sector.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine compensation event.

Next Steps

• Continued quarterly vesting of remaining RSU awards for the reporting person.

Key Dates

Keywords

Monopar Therapeutics, MNPR, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units